Portfolio Company Exonate Ltd. lead candidate EXN407 demonstrates safety and biological activity in phase Ib/IIa clinical trial Stoic VCMarch 5, 2024 - < 1 min read https://stoicvc.com.au/wp-content/uploads/2024/04/ion-fet-QRawWgV6gmo-unsplash-scaled.jpg 1707 2560 Stoic VC https://stoicvc.com.au/wp-content/uploads/2023/04/Screen-Shot-2023-04-25-at-5.44.30-pm-300x137.png Stoic VC2024-03-05 15:40:512024-06-06 10:10:17Portfolio Company Exonate Ltd. lead candidate EXN407 demonstrates safety and biological activity in phase Ib/IIa clinical trial
